This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Centene (CNC) Eyes Membership Growth With 2024 Expansion Plans
by Zacks Equity Research
Centene (CNC) declares the availability of a varied set of health plans across new counties in 2024. It, thereby, places intensified focus on growing its Medicare business.
If You Invested $1000 in Molina a Decade Ago, This is How Much It'd Be Worth Now
by Zacks Equity Research
Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.
Here's Why You Should Hold UnitedHealth Group (UNH) Stock Now
by Zacks Equity Research
Growing Membership, expanding government business, strategic acquisitions, improving operating margin and solid 2024 plans poise UnitedHealth Group (UNH) well for growth.
Here's Why Investors Should Retain Humana (HUM) Stock Now
by Zacks Equity Research
Humana (HUM) benefits from an upgraded health plan offering suite, expanding Medicare Advantage membership and solid cash reserves.
UnitedHealth Group (UNH) to Expand Coverage Area in 2024
by Zacks Equity Research
UnitedHealth Group (UNH) is set to enhance its offerings with UCard and expand to 110 new counties in 2024 with its Individual Medicare Advantage Plan.
Here's Why Molina (MOH) is a Strong Growth Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Should Value Investors Buy Molina Healthcare (MOH) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
The Zacks Analyst Blog Highlights Molina Healthcare, Dr. Reddy's Laboratories and NeuroBo Pharmaceuticals
by Zacks Equity Research
Molina Healthcare, Dr. Reddy's Laboratories and NeuroBo Pharmaceuticals are part of the Zacks top Analyst Blog.
4 Stocks That Stand Out on Attractive Interest Coverage Ratio
by Sumit Singh
A company that is capable of generating earnings well above its interest expense can withstand financial hardship. MOD, SFM, MOH and MCK are sound enough to meet financial obligations.
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Want to Shrug Off Volatility? Buy 3 Medical Growth Stocks
by Indrajit Bandyopadhyay
We pick three medical stocks - MOH, RDY and NRBO - that have gained more than 5% in the past three months amid market volatility.
Is Alcon (ALC) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Alcon (ALC) and Molina (MOH) have performed compared to their sector so far this year.
If You Invested $1000 in Molina a Decade Ago, This is How Much It'd Be Worth Now
by Zacks Equity Research
Holding on to popular or trending stocks for the long-term can make your portfolio a winner.
Are Investors Undervaluing Molina Healthcare (MOH) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Here's Why Molina (MOH) is a Strong Value Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Add These 4 Stocks With Remarkable Interest Coverage Ratio
by Sumit Singh
A company that is capable of generating earnings well above its interest expense can withstand financial hardship. STRL, SFM, MOH and MCK are sound enough to meet financial obligations.
Why Molina (MOH) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's Why You Should Retain Centene (CNC) in Your Portfolio
by Zacks Equity Research
Strong growth in membership, contract wins, accretive acquisitions and streamlining of businesses poise Centene (CNC) well for growth.
Community Health (CYH), Mindoula to Offer Mental Health Care
by Zacks Equity Research
Community Health (CYH) collaborates with Mindoula to enhance the availability of behavioral health resources to its affiliated provider network, who can now treat patients better.
3 Reasons Growth Investors Will Love Molina (MOH)
by Zacks Equity Research
Molina (MOH) could produce exceptional returns because of its solid growth attributes.
Molina Healthcare (MOH) Closes $150M My Choice Wisconsin Buyout
by Zacks Equity Research
Molina Healthcare (MOH) completes the My Choice Wisconsin acquisition ahead of the updated scheduled time.
Factors That Make Molina Healthcare (MOH) an Attractive Bet Now
by Zacks Equity Research
Molina Healthcare (MOH) remains well-poised for growth on a growing customer base, acquisitions and solid cash reserves.
Humana (HUM) Down 5.2% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Humana (HUM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why Investors Should Hold Humana (HUM) in Portfolio
by Zacks Equity Research
Humana (HUM) remains well-poised for growth on the back of an expanding Medicare Advantage membership, upgraded health plan offering suite and solid cash reserves.
HCA Healthcare (HCA) & Google Cloud Unite to Improve Efficiency
by Zacks Equity Research
HCA Healthcare (HCA) partners with Google Cloud to improve and automate workflows.